Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
dc.contributor.author | Baker, D | en_US |
dc.contributor.author | Herrod, SS | en_US |
dc.contributor.author | Alvarez-Gonzalez, C | en_US |
dc.contributor.author | Giovannoni, G | en_US |
dc.contributor.author | Schmierer, K | en_US |
dc.date.accessioned | 2017-08-29T13:15:27Z | |
dc.date.available | 2017-03-24 | en_US |
dc.date.issued | 2017-08 | en_US |
dc.date.submitted | 2017-04-04T10:19:16.278Z | |
dc.identifier.issn | 2168-6149 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/25508 | |
dc.format.extent | 961 - 969 | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | JAMA NEUROLOGY | en_US |
dc.title | Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab | en_US |
dc.type | Article | |
dc.rights.holder | (c) American Medical Association (AMA) | |
dc.identifier.doi | 10.1001/jamaneurol.2017.0676 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407688300016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 8 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 74 | en_US |